XTLB

NASDAQ

XTL Biopharmaceuticals Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

$2.52+0.08 (+3.48%)

News25/Ratings0

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

News · 26 weeks22-100%

2025-10-262026-04-19

Mix1290d

SEC Filings7(58%)
Other2(17%)
Insider2(17%)
Leadership1(8%)

Latest news

25 items

31dINSIDER
SEC Form 3 filed by new insider Segal Niv
3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)
31dINSIDER
SEC Form 3 filed by new insider Hillel Fain Osnat
3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)
34dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
34dPR
XTL Biopharmaceuticals Announces ADS Ratio Change
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on March 25, 2026 (the "Effective Date"). For the Company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-four revers
44dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
55dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
55dPR
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari
58dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
59dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
65dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
84dPR
XTL Update on Recent Developments
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company's Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million. Management of the Company believes that the completion of the proposed transaction to acquire 85% of the shares of NeuroNOS Ltd.,
85dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
90dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
90dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
90dPR
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders' equity for continued listing. This Nasdaq determination was based on (i) the Company's Form 6-K, dated December 30, 2025, that included financial information for the period ended June 30, 2025,
100dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
100dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
114dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
115dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
120dPR
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated December 22, 2025, notifying the Company that based on XTL's closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. The Nasdaq notification letter does not result in the immediate delisting of the Company's American Depositary Shares
132dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
139dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
182dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
269dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
276dSEC
SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)